Search Results

Shenzhen Chipscreen Biosciences Co., Ltd. announced that the company’s lead innovative product Chidamide, an oral subtype-selective histone deacetylase inhibitor, combined with R-CHOP, has been officially approved by the National Medical Products Administration for treatment of previously untreated diffuse large B-cell lymphoma with positive MYC and BCL2 expression.

Shenzhen Chipscreen Biosciences Co., Ltd. received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration through its wholly-owned subsidiary, Chengdu Chipscreen Pharmaceutical Co., Ltd.

On March 18 2024, Shenzhen chipscreen biosciences Co., Ltd. (hereinafter referred to as “chipscreen biosciences”, stock code: 688321. SH) announced that the Phase II clinical trial (CGZ203 study) of chiglitazar monotherapy for non-alcoholic steatohepatitis (NASH) was successfully completed with data cleaning and database locking on February 22, 2024.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. today announced that its wholly owned subsidiary, Eucure has reached an exclusive licensing agreement with Chipscreen NewWay Biosciences (“Chipscreen NewWay”), a holding subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd. (“Chipscreen Biosciences”, SSE: 688321) for the clinical development and commercialization of bispecific antibody YH008 in Greater China (including Mainland China, Hong Kong, Macau and Taiwan).

Chengdu Chipscreen NewWay Biosciences Co., Ltd. announced that on January 5, 2024, the dosing of the first patient for a phase I clinical trial of a PD-1/CD40 bispecific antibody, NWY001, at Sun Yat-Sen University Cancer Center in China, the trial-leading institution.

Rational Vaccines and Shenzhen Mellow Hope Pharm Industrial Co., Ltd. announced they have reached an agreement to jointly develop, manufacture, and commercialize live vaccines against herpes simplex viruses.

Novotech, the global full-service clinical Contract Research Organization that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, announced it has signed a Memorandum of Understanding with Hong Kong-Shenzhen Innovation and Technology Park Limited.

Bowen Acquisition Corp, a special purpose acquisition company, announced the execution of an agreement and plan of merger with Shenzhen Qianzhi BioTechnology Co., Ltd, a biotech company engaged in development, manufacturing and sales of ozonated health and wellness products in China.

Shenzhen Chipscreen Biosciences’ licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Chidamide (Tucidinostat, also known as Epidaza ®, Hiyasta®, HBI-8000) monotherapy for the treatment of relapsed or refractory (R/R) PTCL by the Ministry of Health, Labour and Welfare in Japan.